PGNX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Progenics Pharmaceuticals Inc's EBITDA per share for the three months ended in Mar. 2016 was $-0.17. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2016 was $-0.58.
During the past 12 months, the average EBITDA per Share Growth Rate of Progenics Pharmaceuticals Inc was -3973.30% per year. During the past 3 years, the average EBITDA per Share Growth Rate was -17.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.
During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of Progenics Pharmaceuticals Inc was 51.10% per year. The lowest was -46.40% per year. And the median was -8.10% per year.
Progenics Pharmaceuticals Inc's EBITDA for the three months ended in Mar. 2016 was $-11.97 Mil.
During the past 12 months, the average EBITDA Growth Rate of Progenics Pharmaceuticals Inc was -1469.70% per year. During the past 3 years, the average EBITDA Growth Rate was 4.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.
During the past 13 years, the highest 3-Year average EBITDA Growth Rate of Progenics Pharmaceuticals Inc was 56.30% per year. The lowest was -31.90% per year. And the median was 5.40% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the companys stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Progenics Pharmaceuticals Inc's EBITDA per share for the fiscal year that ended in Dec. 2015 is calculated as
Progenics Pharmaceuticals Inc's EBITDA per share for the quarter that ended in Mar. 2016 is calculated as
Progenics Pharmaceuticals Inc EBITDA per Share for the trailing twelve months (TTM) ended in Mar. 2016 was -0.166 (Jun. 2015 ) + -0.142 (Sep. 2015 ) + -0.102 (Dec. 2015 ) + -0.171 (Mar. 2016 ) = $-0.58
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.
While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.
The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.
EBITDA can be thought of as the cash a business generates that is available to: Add more inventory
EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Todays depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.
A companys depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.
Analysts use EBITDA to remove this element of personal choice from a companys accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.
Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EDITDA because in this calculation, depreciation is not counted as an expense.
EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also price/EBITDA is sometimes used in valuations.
Progenics Pharmaceuticals Inc Annual Data
Progenics Pharmaceuticals Inc Quarterly Data